Breaking news from across the pharma sector
Drug Discovery 2024: Connecting Minds, Transforming Science, Empowering Community will take place at ExCeL London from 2–3 October
Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Patrick Cushing PhD, has been promoted to vice president operations of Rentschler Biopharma, Inc., the company’s US subsidiary, effective 1 May 2024.
Dr Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology and infectious diseases.
Biopharma Group is hosting the 3rd edition of the popular freeze drying seminar series at the University of Cambridge. This year, the focus is on "Freeze Drying of In Vitro Diagnostics".
• Stable lentiviral (LV) cell line development service achieves unconcentrated titers >1E9 TU/mL for therapeutic transgenes. • Fully stable cell lines have all viral genes and transgene stably integrated, enabling biomanufacturing scalability and a more robust production process. • Transfection-free lentiviral manufacturing eliminates GMP plasmid cost and reduces supply chain risk for cell and gene therapy developers.
SPT Labtech, a global leader in the design, development and manufacture of automated instrumentation and consumables for life science applications, is pleased to announce a partnership with BioLabs, the global innovation support platform.
Today, family-run community pharmacy chain Jardines Pharmacy (“Jardines”), primarily based in Milton Keynes and Bedfordshire, announces the launch of the Jardines Pharmacy app in collaboration with Charac, the UK’s premier patient relationship management platform for pharmacies. Charac’s platform will help Jardines digitalise its services, improving operational effectiveness and customer satisfaction.
Regeneron Pharmaceuticals, Inc today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Baltimore, Maryland, from May 7 to 11, 2024.
The European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunteer-led organisation for the drug discovery community, today entered into a partnership with SRG, leaders in life science recruitment, to support the advancement of science professionals in their careers.
A variety of factors like powder flow, material characteristics, compression pressure, turret speed, etc can affect tablet quality and production run time. Any resulting tablet defects can exacerbate production costs or even result in no product at all! Therefore, it’s necessary to characterise the tablet compression process to achieve robust tablets.
: Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Debiopharm, a biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases. The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.
Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.